Buckhead Capital Management LLC Purchases 7,368 Shares of The Cooper Companies, Inc. $COO

Buckhead Capital Management LLC raised its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 14.3% during the third quarter, HoldingsChannel.com reports. The firm owned 58,930 shares of the medical device company’s stock after buying an additional 7,368 shares during the period. Cooper Companies accounts for 1.5% of Buckhead Capital Management LLC’s portfolio, making the stock its 27th biggest position. Buckhead Capital Management LLC’s holdings in Cooper Companies were worth $4,040,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of COO. Czech National Bank raised its holdings in shares of Cooper Companies by 3.7% in the third quarter. Czech National Bank now owns 50,673 shares of the medical device company’s stock worth $3,474,000 after buying an additional 1,791 shares during the last quarter. Caldwell Trust Co purchased a new stake in Cooper Companies during the second quarter worth $274,000. Orion Porfolio Solutions LLC grew its position in shares of Cooper Companies by 840.5% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 96,592 shares of the medical device company’s stock valued at $6,873,000 after acquiring an additional 86,322 shares during the period. Squarepoint Ops LLC grew its holdings in Cooper Companies by 116.5% in the second quarter. Squarepoint Ops LLC now owns 42,134 shares of the medical device company’s stock valued at $2,998,000 after purchasing an additional 22,676 shares during the period. Finally, State of Wyoming acquired a new stake in Cooper Companies in the 2nd quarter valued at $220,000. 24.39% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

COO has been the topic of several research analyst reports. Barclays reiterated an “overweight” rating and issued a $91.00 price objective on shares of Cooper Companies in a report on Monday, December 8th. Piper Sandler reaffirmed an “overweight” rating and set a $94.00 target price (up from $83.00) on shares of Cooper Companies in a research note on Friday, December 5th. JPMorgan Chase & Co. lifted their target price on Cooper Companies from $66.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, December 5th. Weiss Ratings restated a “sell (d+)” rating on shares of Cooper Companies in a report on Monday. Finally, KeyCorp restated a “sector weight” rating on shares of Cooper Companies in a report on Friday, December 5th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.15.

Cooper Companies Price Performance

Shares of NASDAQ COO opened at $82.46 on Friday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.13 and a current ratio of 1.89. The Cooper Companies, Inc. has a fifty-two week low of $61.78 and a fifty-two week high of $100.24. The stock’s 50-day simple moving average is $74.41 and its 200-day simple moving average is $71.89. The firm has a market capitalization of $16.16 billion, a PE ratio of 43.86, a price-to-earnings-growth ratio of 2.35 and a beta of 1.05.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.11 by $0.04. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. The business had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter in the prior year, the business posted $1.04 EPS. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. As a group, equities research analysts forecast that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies declared that its Board of Directors has approved a share buyback program on Wednesday, September 17th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical device company to buy up to 15.4% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling at Cooper Companies

In other news, CEO Albert G. White III acquired 10,000 shares of Cooper Companies stock in a transaction on Tuesday, December 16th. The stock was bought at an average price of $80.80 per share, for a total transaction of $808,000.00. Following the completion of the purchase, the chief executive officer owned 236,151 shares in the company, valued at $19,081,000.80. This represents a 4.42% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Lawrence Erik Kurzius purchased 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were acquired at an average price of $82.50 per share, with a total value of $165,000.00. Following the purchase, the director owned 7,777 shares in the company, valued at $641,602.50. This trade represents a 34.62% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders bought 15,230 shares of company stock worth $1,209,103. 1.98% of the stock is owned by insiders.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.